Nakamura Y - Search Results

1

Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.

Inoue Y, Ikegami Y, Sano K, Suzuki T, Yoshida H, Nakamura Y, Nakagawa H, Ishikawa T. Inoue Y, et al. Among authors: nakamura y. Chemotherapy. 2013;59(4):260-72. doi: 10.1159/000357772. Epub 2014 Jan 17. Chemotherapy. 2013. PMID: 24457609

2

Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.

Nakamura Y, Satake K, Sano K, Ito A, Yoshikawa M, Ikegami Y, Yoshida H, Nakano H, Oka M, Sawada S, Soda H, Kohno S. Nakamura Y, et al. Chemotherapy. 2008;54(6):485-91. doi: 10.1159/000159625. Epub 2008 Oct 3. Chemotherapy. 2008. PMID: 18832822

3

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.

Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.

4

Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. Shiozawa K, et al. Among authors: nakamura y. Int J Cancer. 2004 Jan 1;108(1):146-51. doi: 10.1002/ijc.11528. Int J Cancer. 2004. PMID: 14618629

5

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S. Nakamura Y, et al. Cancer Res. 2005 Feb 15;65(4):1541-6. doi: 10.1158/0008-5472.CAN-03-2417. Cancer Res. 2005. PMID: 15735043

6

Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.

Inoue Y, Morita T, Onozuka M, Saito KI, Sano K, Hanada K, Kondo M, Nakamura Y, Kishino T, Nakagawa H, Ikegami Y. Inoue Y, et al. Among authors: nakamura y. Cells. 2019 Jul 23;8(7):763. doi: 10.3390/cells8070763. Cells. 2019. PMID: 31340525 Free PMC article.

7

Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.

Nakamura Y, Sano K, Soda H, Takatani H, Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K, Kohno S. Nakamura Y, et al. J Thorac Oncol. 2010 Sep;5(9):1404-9. doi: 10.1097/JTO.0b013e3181e59a7b. J Thorac Oncol. 2010. PMID: 20651613 Free article.

8

Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.

Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, Takemoto S, Fukuda M, Nagashima S, Iida T, Tsukamoto K, Kohno S. Motoshima K, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2013 Dec;72(6):1299-1304. doi: 10.1007/s00280-013-2307-6. Cancer Chemother Pharmacol. 2013. PMID: 24121455 Clinical Trial.

9

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S. Nagashima S, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2006 Nov;58(5):594-600. doi: 10.1007/s00280-006-0212-y. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16520985

10

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.

Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S. Yamaguchi H, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 20401612 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,500 results

Search Page

Filters